Methylene amine substituted arylindenopyrimidines as potent adenosine A2A/A1 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 9, 2010, Pages 2864-2867

  Shook, Brian C ^a   Rassnick, Stefanie ^a   Hall, Daniel ^a   Rupert, Kenneth C ^a   Heintzelman, Geoffrey R ^a   Hansen, Kristen ^a   Chakravarty, Devraj ^a   Bullington, James L ^a   Scannevin, Robert H ^a   Magliaro, Brian ^a   Westover, Lori ^a   Carroll, Karen ^a   Lampron, Lisa ^a   Russell, Ronald ^a   Branum, Shawn ^a   Wells, Kenneth ^a   Damon, Sandra ^a   Youells, Scott ^a   Li, Xun ^a   Osbourne, Mel ^a   Demarest, Keith ^a   Tang, Yuting ^a   Rhodes, Kenneth ^a   Jackson, Paul F ^a   more..

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

A1 antagonists; A2A antagonists; Adenosine antagonists; Catalepsy; Dopamine; Parkinson's disease

Indexed keywords

ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; AMINE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; MOUSE; NONHUMAN; PARKINSON DISEASE; REACTION OPTIMIZATION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

AMINES; ANIMALS; CATALEPSY; DISEASE MODELS, ANIMAL; MICE; NEUROTRANSMITTER AGENTS; PYRIMIDINES; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950953195     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.03.042     Document Type: Article

References (24)

1. Lozano A.M., Lang A.E., Hutchison W.D., and Dostrovsky J.O. Curr. Opin. Neurobiol. 8 (1998) 783
2. Muller C.E., and Scior T. Pharm. Acta Helv. 68 (1993) 77
3. DeNinno M.P. Annu. Rep. Med. Chem. 33 (1998) 111
4. Pires V.A., Pamplona F.A., Pandolfon P., Fernandes D., Prediger R.D.S., and Takahashi R.N. Behav. Pharmacol. 20 (2009) 134
5. Davidson D.A., and Weidley E. Life Sci. 18 (1976) 1279-1284
6. Fredholm B.B., Abbraccio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., and Williams M. Pharmacol. Rev. 46 (1994) 143
7. Dunwiddie T.V., and Masino S.A. Annu. Rev. Neurosci. 24 (2001) 31
8. Jacobson K.A., van Galen P.J.M., and Williams M. J. Med. Chem. 35 (1992) 4007
9. Muller C.E. Drugs Future 25 (2000) 1043
10. Bara-Himenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., and Chase T.N. Neurology 61 (2003) 293
11. Heintzelman, G. R.; Bullington, J. L.; Rupert, K. C. WO Patent 2005042500.
12. Bullington J.L., Cameron J.C., Davis J.E., Dodd J.H., Harris C.A., Henry J.R., Lee Pellegrino-Gensey J., Rupert K.C., and Siekierka J.J. Bioorg. Med. Chem. Lett. 8 (1998) 2489
13. Zarrindast M.R., Modabber M., and Sabetkasai M. Pyschopharamcology 113 (1993) 257
14. Schwarzschild M.A., Agnati L., Fuxe K., Chen J.F., and Morelli M. Trends Neurosci. 29 (2006) 647
15. Ames B., Lee F., and Durston W. Proc. Natl. Acad. Sci. 70 (1973) 782
16. Buckle D.R., Morgan N.J., Ross J.W., Smith H., and Spicer B.A. J. Med. Chem. 16 (1973) 1334
17. Mashraqui S.H., and Hariharasubrahmanian H. J. Chem. Res., Synopses (1999) 492
18. Hentges S.G., and Sharpless K.B. J. Am. Chem. Soc. 102 (1980) 4263
19. Saha M., Das T.K., Das A., and Ghosh N.R. Synth. Commun. 20 (1990) 137
20. Abdel-Magid A.F., Carson K.G., Harris B.D., Maryanoff C.A., and Shah R.D. J. Org. Chem. 61 (1996) 3849
21. Kraus G.A., and Sy J.O. J. Org. Chem. 54 (1989) 77
22. Yu Y., and Liebeskind L.S. J. Org. Chem. 69 (2004) 3554
23. Kusturin C., Liebeskind L.S., Rahman H., Sample K., Schweitzer B., Srogl J., and Neumann W.L. Org. Lett. 5 (2003) 4349
24. Liebeskind L.S., and Srogl J. Org. Lett. 4 (2002) 979